Numan Operations Limited (9011408) - Improvement action plan

The pharmacy does not have sufficient assurances that the prescribing service it works with consistently verifies people's health information independently before prescribing weight loss medicines. This means that it cannot always be sure that the prescribing is safe and clinically appropriate.

The prescribing service, Numan, has committed to improving their processes of independent verification by implementing the following process changes:
● Mandate GP notification of prescribed treatment from 29/10/25.
Mitigates the risk of fragmented care and ensures the patient’s GP is aware of treatment, supporting continuity of care and early identification of contraindications or complications.
● Route all patients from Scotland, Wales, or those without NHS record access/consent to a video call from 29/10/25.
Mitigates the risk of prescribing relying on online consultation and photographic evidence alone.
● Require real-time photos only (no gallery uploads). This means photos must be taken live with their device’s camera during onboarding from 30/10/25.
Reduces the risk of manipulated, reused, or AI-generated images.
● Check all photos for manipulation using image-manipulation-detection tooling from 6/11/25.
Further mitigates the risk of edited or manipulated images influencing clinical decisions.
● If potential image-manipulation detected, route the patient to a video call for verification from 6/11/25. Ensures further verification required where image integrity is uncertain.
● Review NHS records for a weight recorded within the last 6 months from 6/11/25.
Ensures weight data used for prescribing is recent and clinically reliable.
● If no recent weight on NHS records and BMI 25–30, route to video call from 6/11/25.
Mitigates the risk of treating patients who do not meet weight-based eligibility criteria.
● If no recent weight and BMI >30, allow asynchronous review only if the clinician has no doubt the patient meets eligibility based on their authentic photos (from 6/11/25).
Prevents inappropriate prescribing while allowing safe clinical judgement where obesity is clearly evident.
● During asynchronous review, route to video call if any clinical queries arise from 6/11/25.
Mitigates clinical risk by ensuring uncertainties are resolved through direct assessment.